Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$31.50 USD
-6.36 (-16.80%)
Updated May 10, 2024 04:00 PM ET
After-Market: $31.05 -0.45 (-1.43%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
COLL 31.50 -6.36(-16.80%)
Will COLL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for COLL
Collegium downgraded by Piper Sandler over valuation
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
Collegium Pharmaceutical Reports First Quarter 2024 Earnings
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Collegium Pharmaceutical (COLL) Gets a Buy from Truist Financial